Belite Bio Inc American Depositary Shares (BLTE)
Stock · NASDAQ · Health Care
$142.78as of 10/16/2026
Price chart
Active signals
BLTE Signal Track Record
How signals performed across all stocks →What BLTE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | +7.2% | 74% | September 2, 2026 |
| Bollinger Band Breakout | 22 | +7.3% | 68% | September 4, 2026 |
| 200-Day Moving Average TouchActive now | 15 | +5.6% | 93% | October 2, 2026 |
| Bollinger Band BreakdownActive now | 13 | +0.9% | 62% | October 6, 2026 |
| Any 20-session window (baseline) | +3.5% | 61% |
Computed by MarketWall from daily closing prices since February 14, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BLTE
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geog…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 41
- Website
- belitebio.com/
Fundamentals
- 1-day range
- $141.66$152.62
- Market cap
- $6.32B
- P/E (trailing)
- —
- P/E (forward)
- 63.18
- EPS (trailing)
- $-2.85
- Dividend yield
- —
- Beta
- -1.21
- Avg. volume
- 185.5K
Forecasts
9 analyst ratings
Belite Bio Inc American Depositary Shares Competitors
Chosen by industry and closest market cap.
- BLTEBelite Bio Inc American Depositary Shares$142.78▼ 6.45%Market cap $6.32BP/E —$78.71$200
- ERASErasca Inc. Common Stock$13.39▼ 9.95%Market cap $6.25BP/E —$2.11$24.28
- XENEXenon Pharmaceuticals Inc. Common Shares$33.49▼ 2.45%Market cap $6.24BP/E —$33.52$72.66
- DNTHDianthus Therapeutics Inc. Common Stock$72.09▼ 3.27%Market cap $6.15BP/E —$32.22$117.88
- LGNDLigand Pharmaceuticals Incorporated Common Stock$295.54▼ 0.99%Market cap $6.02BP/E 30.38$175.89$326.63
- KNSAKiniksa Pharmaceuticals International plc Class A Ordinary Shares$78.59▼ 1.69%Market cap $5.97BP/E 77.33$35.2$82.94
- PTCTPTC Therapeutics Inc. Common Stock$59.24▼ 2.87%Market cap $5.91BP/E —$58.8$90.87
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BLTE Belite Bio Inc American Depositary Shares | $6.32B | — | $142.78 | ▼ 6.45% | $78.71$200 |
| ERAS Erasca Inc. Common Stock | $6.25B | — | $13.39 | ▼ 9.95% | $2.11$24.28 |
| XENE Xenon Pharmaceuticals Inc. Common Shares | $6.24B | — | $33.49 | ▼ 2.45% | $33.52$72.66 |
| DNTH Dianthus Therapeutics Inc. Common Stock | $6.15B | — | $72.09 | ▼ 3.27% | $32.22$117.88 |
| LGND Ligand Pharmaceuticals Incorporated Common Stock | $6.02B | 30.38 | $295.54 | ▼ 0.99% | $175.89$326.63 |
| KNSA Kiniksa Pharmaceuticals International plc Class A Ordinary Shares | $5.97B | 77.33 | $78.59 | ▼ 1.69% | $35.2$82.94 |
| PTCT PTC Therapeutics Inc. Common Stock | $5.91B | — | $59.24 | ▼ 2.87% | $58.8$90.87 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Belite Bio Files Marketing Authorization Application In Singapore, U.K., Switzerland For Tinlarebant To Treat Stargardt Disease Type 1benzinga · 10/14/2026
- Belite Bio Announces Oral Presentations at Two Upcoming Medical ConferencesYahoo · 10/1/2026
- Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/14/2026
Insider Activity
Insider Actions →- Hendrik Peter Scholl · October 1, 2026 · Sale2 @ $170.02
- Hendrik Peter Scholl · October 1, 2026 · Sale14 @ $169.36
- Hendrik Peter Scholl · October 1, 2026 · Sale12 @ $168.21
- Hendrik Peter Scholl · October 1, 2026 · Sale78 @ $167.59
- Hendrik Peter Scholl · October 1, 2026 · Sale50 @ $166.44
- Hendrik Peter Scholl · October 1, 2026 · Sale120 @ $165.49
- Hendrik Peter Scholl · October 1, 2026 · Sale24 @ $164.64
- Hendrik Peter Scholl · October 1, 2026 · Sale200 @ $163.63
- Yu-Hsin Lin · September 8, 2026 · Sale2.7K @ $198.09
- Yu-Hsin Lin · September 8, 2026 · Sale8.8K @ $197.36
- Yu-Hsin Lin · September 8, 2026 · Sale6.1K @ $196.54
- Yu-Hsin Lin · September 8, 2026 · Sale6.1K @ $195.62
- Yu-Hsin Lin · September 8, 2026 · Sale2.4K @ $194.33
- Hao-Yuan Chuang · September 8, 2026 · Sale2.6K @ $198.05
- Hao-Yuan Chuang · September 8, 2026 · Sale4.6K @ $197.23
Institutional Ownership
March 31, 2026
- Total shares held
- 9.12M
- Total value held
- $1.36B
- Institutional holders
- 74
- Unknown3.06M
- Unknown1.11M
- Unknown768.4K
- Unknown715.3K
- Unknown570.1K
- Unknown494.5K
- Unknown357.6K
- Unknown304.0K
- Unknown281.8K
- Unknown201.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
BLTE to Deliver Oral Presentations at Two Medical Conferences
Belite Bio announced that it will give oral presentations at two upcoming medical conferences. The company plans to share data on its pipeline during these sessions. The news arrives as the stock is trading near a long‑standing support level around $153.70, a point that has been tested many times. Investors may watch the conferences for updates that could affect perception of the company's progress.
BLTE to Deliver Oral Presentations at Two Medical Conferences. Belite Bio announced that it will give oral presentations at two upcoming medical conferences. The company plans to share data on its pipeline during these sessions. The news arrives as the stock is trading near a long‑standing support level around $153.70, a point that has been tested many times. Investors may watch the conferences for updates that could affect perception of the company's progress.